Market Place
Sourcing Support
Incannex Announces Positive Results from Phase 2 Psi-GAD1 Trial of Psilocybin
28 Feb 2024 //
NASDAQ
Fortrea inks deal with Incannex for sleep apnea drug trial
27 Jul 2023 //
FIERCE BIOTECH
Incannex Engages Eurofins to Manufacture Topical Therapeutic ReneCann
30 Nov 2022 //
CONTRACTPHARMA
Incannex, Eurofins Enter Development & Mfg. Pact for Addiction Disorder Meds
28 Nov 2022 //
CONTRACT PHARMA
Incannex to manufacture patented medicated chewable anti-addiction products
25 Nov 2022 //
SMALLCAPS
Incannex Healthcare partners with R&D organisation Curia
02 Aug 2022 //
PROACTIVEINVESTORS
Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow
27 Jul 2022 //
PRNEWSWIRE
Incannex Receives Ethics Approval to Commence Ph 1 Clinical Trial Drug IHL-675A
21 Jul 2022 //
PRNEWSWIRE
Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference
27 Jun 2022 //
PRNEWSWIRE
Incannex`s +ve results from PII trial of IHL-42X for obstructive sleep apnoea
03 Jun 2022 //
PRNEWSWIRE
Incannex Announces Positive Pre-IND Meeting with FDA for IHL-42X
17 May 2022 //
PRNEWSWIRE
Incannex Completes Agreement to Wholly Acquire APIRx Pharmaceuticals
12 May 2022 //
PRNEWSWIRE
Incannex announces IHL-216A observed to have a neuroprotective effect
10 May 2022 //
PRNEWSWIRE
Incannex to Acquire APIRx Pharmaceuticals USA, LLC
24 Mar 2022 //
PRNEWSWIRE
Incannex observes reduction in AHI in prelim results of IHL-42X trial
10 Mar 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.